To evaluate the optimum dose of olsalazine for maintaining remission in ulcerative colitis, 198 patients in remission for more than three months were randomly assigned to receive 0.5 g, 1.0 g, or 2.0 g/day for 12 months. A dose-ranging effect was detected in the per protocol analysis, with remission rates of 60% (0.5 g), 70% (1.0 g), and 78% (2.0 g) (p=0.03, trend in proportions). The higher dose was most effective in patients with proctitis (90Gb remission on 2 g/day, p=0.03) or those in remission for less than 12 months before the trial (88% remission on 2 g/day, p=0.0006). There was little dose-ranging effect in patients with extensive colitis or those in remission for more than 12 months. Diarrhoea necessitated treatment withdrawal in 12%. The optimal dose of olsalazine for maintaining remission in ulcerative colitis is 1 g/day. For patients with proctitis or recent relapse, 2 g/day may be preferabJle, although the dose seems to be less important in patients with more extensive disease or those in long term remission.
Olsalazine was developed as an alternative to sulphasalazine for the treatment of ulcerative colitis, in order to avoid the side effects of sulphasalazine attributable to the sulphapyridine moiety.' 2 The drug consists of two molecules of 5-aminosalicylic acid (5-ASA) joined by an azo bond that is split by bacterial azoreductase to release 5-ASA in the colon. 3 Olsalazine is now well established in the treatment of ulcerative colitis. A dose of 1 g/day compared with placebo reduced the six month relapse rate from 45% to 23% in a randomised trial of 160 patients who were intolerant of sulphasalazine,4 and in another study of 162 patients, olsalazine 1 g/day was as effective as sulphasalazine 2 g/day for maintaining remission. 5 This has since been confirmed. 6 Olsalazine is well tolerated by over 80% of patients who are intolerant of sulphasalazine. 4 For maintaining remission with sulphasalazine, Azad Khan et al 7 showed that greater therapeutic efficacy could be obtained by increasing the dose, although 2 g daily was optimal in terms of efficacy with the least side effects. However, whether there is a similar dose response effect for olsalazine when used for maintenance therapy is unknown. In a small study of 66 patients with active ulcerative colitis treated with olsalazine, a higher dose (3 g/day) was more effective than 1.5 g, 0.75 g, or placebo.8 Consequently, a dose-ranging study of olsalazine in the maintenance of remission in ulcerative colitis was designed. Particular attention was paid to the relationship between dose efficacy and the extent of disease and the safety profile of different doses, in view of reports that a small intestinal secretory diarrhoea may be induced by olsalazine.9
Methods

PATIENTS
A total of 198 patients from Oxford or Orebro (99 from each centre) with ulcerative colitis in remission for three or more months were recruited. Ulcerative colitis was diagnosed on standard clinical, endoscopic, histological, and radiological criteria, and remission was defined as no clinical symptoms of active disease and no signs of active inflammation on sigmoidoscopy (grade 0: normal; 1: pink mucosa of quiescent colitis, without visible vessels) *10 The maximum extent of macroscopic disease ever recorded by endoscopy or barium enema was defined as proctitis (-15 cm), left sided (up to the splenic flexure), or subtotal/pancolitis. The study was approved by the ethical committee of each centre.
PROTOCOL
Each patient was randomly assigned to one of three groups receiving 0.5 g, 1-0 g, or 2-0 g enteric coated tablets of olsalazine daily. Tablets were supplied in blister packs and patients were instructed to take two tablets twice daily with food. Each active tablet contained 500 mg olsalazine sodium. Physically indistinguishable placebo tablets (cornstarch and riboflavin sodium phosphate) made up the numbers for patients randomised to 0.5 g or 1-0 g/day and to allow the dose to increase gradually over seven days for those randomised to 2.0 g/day in order to improve patient tolerance. Patients were assessed clinically at three monthly intervals for 12 There were no significant differences between patients in the different dosage group (Table I) . There was, however, a statistically non-significant trend (p=0. 17) for patients in the 0.5 g/day group to have been in longer remission than those in the other two groups.
More patients smoked or took snuff in Orebro (25 of 98) than Oxford (seven of 96, p<0001), and proctitis was more common in Oxford (25 of 96, versus eight of 98 in Orebro, p<0-001). Otherwise, patients from the two centres were similar. All but 13 patients were on some form of maintenance treatment (Table I) . The classification of patients for analysis is shown in Figure 1 . Four patients were excluded from the analysis because they changed their mind and took no study drug (3) or failed to attend any appointment after the initial visit (1). Seventeen patients were excluded from the PP life table analysis because of non-compliance, concomitant medication, or lack of confirmation of remission or relapse by sigmoidoscopy within three weeks of termination of the trial. Another 22 patients were excluded from the PP relapse rate analysis because of withdrawal for adverse reactions (20) or intercurrent disease (2). Noncompliance was assessed by tablet counting and did not exceed 45 doses (25%) in a three month period in any patient.
RELAPSE RATE ANALYSIS
There was a significant decrease in relapse frequencies when the dose ranged from 0.5 g to 2.0 g/day (Table II, A higher dose was most effective in preventing relapse for those patients who had been in remission for less than a year before the start of the study (Table IV) . Dose seemed to be less important for those in longer term remission. There was no initial difference in sigmoidoscopic appearances between patients in short (<12 months) and long (>12 months) term remission: 68% of all patients analysed PP had normal rectal mucosa (grade 0) at the start of the trial, and for those in short or long term remission, the proportions were 60% and 72% respectively.
ADVERSE EVENTS
Adverse events were reported in 90 patients (30 in the 0.5 g group, 26 in the 1-0 g group, and 34 in the 2.0 g group). Thirty two patients withdrew prematurely because of adverse events. Apart from diarrhoea or loose stools (Table V) , events leading to withdrawal were upper respiratory symptoms (3), abdominal pain (2), tinnitus (1), nausea (1), back pain (1), and constipation (1). The frequency of diarrhoea leading to withdrawal was related to dose and the duration of remission, but not to the extent of disease (Table V) 1 or 2 g/day is consistent with previous six month studies comparing olsalazine with placebo4 or sulphasalazine5 over a six month period. In another study comparing 2 g/day balsalazide (0.7 g 5-ASA) to 4 g/day balsalazide, remission rates after 12 months were 45% and 64% respectively.12 The 2 g balsalazide result is very similar to the one with 0.5 g/day olsalazine (0.44 g 5-ASA), which supports the conclusion in a recent review13
that at least 0.8 g/day 5-ASA should be delivered in the colon to maintain remission.
Patients with proctitis showed a more pronounced dose ranging response than those with subtotal or pancolitis (Table III) . Although numbers in the subgroups are small, this is probably a true response because it is consistent with the pharmacokinetics of olsalazine. Olsalazine is split into component 5-ASA molecules by bacterial azoreductase when the compound reaches the caecum.3 14 Maintenance of remission probably depends on the luminal concentration of 5-ASA in the affected area of the colon since it has a local mechanism of action.15 The only study that has examined the colonic distribution of 5-ASA after oral ingestion shows a serial decrease in mucosal concentrations distal to the caecum.16 This study is difficult to interpret, however, as it was performed during accelerated intestinal transit and colonic washout and, furthermore, the concentrations did not bear any relationship to the clinical efficacy of different drugs. Higher doses of olsalazine are more likely to achieve therapeutic concentrations of 5-ASA in the distal colon, which is consistent with the greater benefit of 2 g/day in patients with proctitis. In patients with left sided colitis, no benefit was obtained by increasing the dose from 1 g to 2 g/day.
The results in patients with subtotal or pancolitis are more difficult to interpret as there was no difference between dosage groups. This is possibly because patients in the 0.5 g/day group tended to have a longer median time in remission before entering the study. Patients who had recently relapsed were more sensitive to the dose of olsalazine. In those who had been in remission for less than 12 months, a high dose (2 g/day) was much more effective at preventing relapse than a low dose (0.5 g/day, Table IV ). It has previously been reported that recurrence is more common in patients who have recently relapsed.4 17 The reason for this is not clear, but microscopic evidence of inflammation often persists despite clinical and sigmoidoscopic remission and may predict relapse.'8 Therefore, a higher luminal concentration of 5-ASA may be necessary in the early stages of remission. For those in longer term remission, dose is less important and 0.5 g/day seems to be as effective as a higher dose after two years in remission.
Clinical use of a drug depends on a balance between efficacy and adverse effects. The only side effect of olsalazine that occurs with any frequency is diarrhoea, which can be distinguished from a relapse by the absence of blood and the lack of inflammation at sigmoidoscopy. Diarrhoea is a result of the action of intact olsalazine on the small intestine,19 which seems to be due to an unusual combination of stimulating bicarbonate, chloride, and water secretion and inhibiting absorption.20 21 In the current study, enteric coated olsalazine was formulated in an attempt to reduce the frequency of diarrhoea. Loose motions or diarrhoea affected 28%, however, and was related to dose, although the drug had to be withdrawn in only 12% who were mostly taking 2 g/day (Table V) . Diarrhoea usually started shortly after beginning the drug, but did not occur for several weeks in some patients (Table V) . The high incidence of loose motions may be a result of meticulous reporting of side effects, including those who had looser motions than previously. This was to the advantage of some patients who had a tendency to constipation with proctitis or distal disease. It is also possible that the enteric coated formulation, contrary to expectations, could have contributed to the relatively high incidence of diarrhoea. Although some patients were particularly sensitive to diarrhoea (including two who had to be withdrawn when taking 0.5 g/day), it could often be mitigated by ensuring that the drug was taken with meals. It was anticipated that diarrhoea would predominantly affect patients with extensive disease as a result of impairment of colonic electrolyte and water reabsorption mechanisms. Subgroup analysis failed to confirm this, however, possibly because numbers were small. Compared with 1 g/day, a dose of 2 g/day improves the remission rate from 70 to 78% at one year, but increases the withdrawal because of diarrhoea from 9 to 19%. It is difficult to explain why the patients who had been in remission for longest seemed to be the most sensitive to this side effect (Table V) , although dose seems to be less important for efficacy in this group (Table IV) . The optimum balance between these factors seems to be achieved with 1 g/day. However, proximal constipation is a common clinical problem in distal colitis22 and olsalazine-induced loosening of stools may be turned to therapeutic advantage in some patients.
It can be concluded that a maintenance dose of 2 g/day is recommended for patients with proctitis or for those who have had a recent relapse, if this can be tolerated. Should diarrhoea occur, temporary reduction in the dose and ensuring that the drug is taken with meals may help. The dose of olsalazine necessary to maintain remission is less important for patients with extensive disease, but 0 5 g/day is ineffective for patients who have been in remission for less than 12 months. For most patients the optimum dose of olsalazine is 1 g/day.
